Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Castle Biosciences, Inc. - Common stock (NQ:CSTL)

38.81 +0.84 (+2.21%)
Streaming Delayed Price Updated: 3:54 PM EST, Dec 12, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 254,090
Open 38.93
Bid (Size) 38.80 (100)
Ask (Size) 38.84 (800)
Prev. Close 37.97
Today's Range 38.06 - 39.19
52wk Range 14.59 - 40.61
Shares Outstanding 25,167,365
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
News headline image
Systematic Review and Meta-Analysis Confirms TissueCypher® Outperforms Traditional Pathology or Clinical Factors Alone to Identify Patients at Increased Risk of Developing Esophageal Cancer
Across multiple published studies, the test consistently identifies high-risk patients whose progression rates exceed guideline-based actionable thresholds for intensified care 
From Castle Biosciences, Inc.
Via GlobeNewswire
News headline image
Expert Melanoma Panel Recommends Castle Biosciences’ DecisionDx®-Melanoma as a Best-Practice Tool for Managing Patients with Melanoma
Expert panel offers data-driven guidance for integrating DecisionDx-Melanoma into clinical decision-making for patients with melanoma 
From Castle Biosciences, Inc.
Via GlobeNewswire

Performance

YTD
+38.4%
+38.4%
1 Month
+11.0%
+11.0%
3 Month
+70.6%
+70.6%
6 Month
+106.2%
+106.2%
1 Year
+31.6%
+31.6%

More News

Read More
News headline image
Earnings Scheduled For November 3, 2025 ↗
Via Benzinga
News headline image
Castle Biosciences Earns a Houston Chronicle Top Workplaces Award for the Fifth Consecutive Year
From Castle Biosciences, Inc.
Via GlobeNewswire
News headline image
New Data Confirms Performance of DecisionDx®-Melanoma to Identify Patients with Less Than Five Percent Risk of Sentinel Lymph Node Positivity
From Castle Biosciences, Inc.
Via GlobeNewswire
News headline image
Castle Biosciences to Present at the Piper Sandler 37th Annual Healthcare Conference
From Castle Biosciences, Inc.
Via GlobeNewswire
News headline image
Why Castle Biosciences' Rally Might Just Be Getting Started ↗
Via Benzinga
News headline image
AMD To Rally Around 12%? Here Are 10 Top Analyst Forecasts For Wednesday ↗
Via Benzinga
News headline image
Castle Biosciences Reports Third Quarter 2025 Results
From Castle Biosciences, Inc.
Via GlobeNewswire
News headline image
Castle Biosciences Launches AdvanceAD-Tx™ to Help Guide Systemic Treatment Decision Making in Patients with Moderate-to-Severe Atopic Dermatitis
From Castle Biosciences, Inc.
Via GlobeNewswire
News headline image
A Glimpse of Castle Biosciences's Earnings Potential ↗
Via Benzinga
News headline image
Castle Biosciences to Participate in Upcoming Investor Conferences
From Castle Biosciences, Inc.
Via GlobeNewswire
News headline image
New Data at American College of Gastroenterology Annual Meeting Show TissueCypher® Provides Actionable Risk Insights that Influence Clinical Management and Prompt Risk-Aligned Intervention in Barrett’s Esophagus
From Castle Biosciences, Inc.
Via GlobeNewswire
News headline image
New Analysis of 13,560 Patients Demonstrates DecisionDx®-Melanoma Stratifies Risk Across Histological Subtypes; Findings to be Presented at Fall Clinical Dermatology Conference
From Castle Biosciences, Inc.
Via GlobeNewswire
News headline image
Castle Biosciences to Release Third Quarter 2025 Financial Results and Host Conference Call on Monday, Nov. 3, 2025
From Castle Biosciences, Inc.
Via GlobeNewswire
News headline image
Castle Biosciences’ Founder, President and CEO Derek Maetzold Honored with the CEO of the Year Award by The CEO Magazine
From Castle Biosciences, Inc.
Via GlobeNewswire
News headline image
Castle Biosciences Honored with a Greater Pittsburgh Top Workplaces 2025 Award
From Castle Biosciences, Inc.
Via GlobeNewswire
News headline image
Castle Biosciences Named One of Newsweek’s America’s Greatest Companies 2025
From Castle Biosciences, Inc.
Via GlobeNewswire
News headline image
New Data at American Foregut Society's 2025 Annual Meeting Demonstrates TissueCypher® Can Detect High-Risk Barrett’s Esophagus Patients Not Identified by Pathology to Support Improved Care Decisions
From Castle Biosciences, Inc.
Via GlobeNewswire
News headline image
New Evidence Published Supporting Use of DecisionDx®-SCC Test in Guiding and Improving Treatment Pathway Decisions in NCCN High-Risk Cutaneous Squamous Cell Carcinoma
From Castle Biosciences, Inc.
Via GlobeNewswire
News headline image
Castle Biosciences to Participate in Upcoming Investor Conferences
From Castle Biosciences, Inc.
Via GlobeNewswire
News headline image
Here are the top movers in Tuesday's session. ↗
Via Chartmill
News headline image
12 Health Care Stocks Moving In Tuesday's Intraday Session ↗
Via Benzinga
News headline image
Tuesday's session: top gainers and losers ↗
Via Chartmill
News headline image
Sterling Infrastructure Posts Better-Than-Expected Earnings, Joins Lemonade, DigitalOcean Holdings, Lattice Semiconductor And Other Big Stocks Moving Higher On Tuesday ↗
Via Benzinga

Frequently Asked Questions

Is Castle Biosciences, Inc. - Common stock publicly traded?
Yes, Castle Biosciences, Inc. - Common stock is publicly traded.
What exchange does Castle Biosciences, Inc. - Common stock trade on?
Castle Biosciences, Inc. - Common stock trades on the Nasdaq Stock Market
What is the ticker symbol for Castle Biosciences, Inc. - Common stock?
The ticker symbol for Castle Biosciences, Inc. - Common stock is CSTL on the Nasdaq Stock Market
What is the current price of Castle Biosciences, Inc. - Common stock?
The current price of Castle Biosciences, Inc. - Common stock is 38.81
When was Castle Biosciences, Inc. - Common stock last traded?
The last trade of Castle Biosciences, Inc. - Common stock was at 12/12/25 03:54 PM ET
What is the market capitalization of Castle Biosciences, Inc. - Common stock?
The market capitalization of Castle Biosciences, Inc. - Common stock is 976.75M
How many shares of Castle Biosciences, Inc. - Common stock are outstanding?
Castle Biosciences, Inc. - Common stock has 977M shares outstanding.
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.